Filing Flows › ADC Therapeutics SA (ADCT) › Q3 2026 › vs Q2 2026
ADC Therapeutics SA (ADCT) Q3 2026 vs Q2 2026 (quarter over quarter)
ADC Therapeutics SA's revenue rose $2.5M (+13%) from $19.2M in Q2 2026 to $21.7M in Q3 2026.
ADC Therapeutics SA, Q3 2026: revenue $21.7M (+32% year over year), operating margin -66.1%, net loss $25.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $21.7M | $19.2M | $2.5M | +13% |
| Net loss | $25.3M | $16.6M | $8.7M | +53% |
| Costs & expenses | $47.0M | $44.7M | $2.4M | +5% |
| Operating costs | $36.1M | $44.7M | −$8.6M | -19% |
| Interest & other, net | $11.0M | −$8.8M | $19.8M | — |
| Research & development | $14.7M | $17.4M | −$2.6M | -15% |
| Sales & marketing | $8.7M | $12.6M | −$3.9M | -31% |
| General & admin | $10.7M | $9.7M | $1.0M | +11% |
| Other operating costs | $1.9M | $5.0M | −$3.1M | -62% |
Questions
How much did ADC Therapeutics SA's revenue grow quarter over quarter in Q3 2026?
ADC Therapeutics SA's revenue rose $2.5M (+13%) from $19.2M in Q2 2026 to $21.7M in Q3 2026.